Company Overview and News

2
ASX listing issues hit once Turnbull-backed PlayUp

2018-04-15 theage.com.au
PlayUp, a fantasy sports gambling outfit previously backed by the family of Prime Minister Malcolm Turnbull, is hoping to raise $US40 million ($51.5 million) through a listing on the Australian Securities Exchange.

 
ASX listing issues hit once Turnbull-backed PlayUp

2018-04-15 smh.com.au
PlayUp, a fantasy sports gambling outfit previously backed by the family of Prime Minister Malcolm Turnbull, is hoping to raise $US40 million ($51.5 million) through a listing on the Australian Securities Exchange.

 
Mission NewEnergy Ltd gets ready to pounce

2016-11-23 proactiveinvestors.com.au
The halt will remain in place until the opening of trade on Monday 28th November 2016, or earlier if an announcement is made to the market.

 
Appendix 4C - quarterly

2016-04-26 asx.com.au

 
Mission NewEnergy Form EX-99.1

2016-01-28 sec.gov
  Exhibit 99.1     Appendix 4C Quarterly report for entities Admitted on the basis of commitments     Rule 4.7B Appendix 4C   Quarterly report For entities admitted On the basis of commitments   Introduced 31/3/2000. Amended 30/9/2001, 24/10/2005.   Name of entity Mission New Energy Limited   ABN   Quarter ended (“current quarter”) 63 117 065 719   31 December 2015   Consolidated statement of cash flows   Cash flows related to operating activities Current quarter $A’000 Year to date (3 months) $

 
Mission NewEnergy Form 6-K (Current Report of Foreign Issuer)

2016-01-28 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934   For the month of January 2016   Commission File Number: 001-35022   Mission NewEnergy Limited (Translation of registrant’s name into English)   Unit B9, 431 Roberts Rd Subiaco, Western Australia 6008 Australia (Address of principal executive office)    Indicate by check mark whether the registrant files

 
Appendix 4C - quarterly

2016-01-27 asx.com.au

 
Mission NewEnergy Form EX-99.2

2015-11-30 sec.gov
  Exhibit 99.2     25 November 2015     CHIEF EXECUTIVE OFFICERS ADDRESS TO THE 2015 ANNUAL GENERAL MEETING OF MISSION NEWENERGY LIMITED   Thank you, Mr Chairman.   On behalf of my fellow directors of the company, I also bid you a warm welcome to the 2015 Annual General Meeting of Mission NewEnergy Limited.   The Annual report which was available to all shareholders a month ago has most of the facts & figures of the year under review.

 
Mission NewEnergy Form EX-99.1

2015-11-30 sec.gov
  Exhibit 99.1         Unit B9, 431 Roberts Rd, Subiaco WA 6008   Tel: + 618 (08) 6313 3975 Fax: + 618 (08) 6270 6339 Email: [email protected] Website: www.missionnewenergy.com      25 November 2015 ASX ANNOUNCEMENT   RESULTS OF RESOLUTIONS PASSED AT THE ANNUAL GENERAL MEETING   Mission NewEnergy Limited advises that at the Annual General Meeting held today, all the resolutions put to the members were passed on a show of hands.

 
Mission NewEnergy Form 6-K (Current Report of Foreign Issuer)

2015-11-30 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934   For the month of November 2015   Commission File Number: 001-35022   Mission NewEnergy Limited (Translation of registrant’s name into English)   Unit B9, 431 Roberts Rd Subiaco, Western Australia 6008 Australia (Address of principal executive office)     Indicate by check mark whether the registrant file

 
 
CEO's Address to Shareholders

2015-11-25 asx.com.au

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...